Abstract: Described herein are pharmaceutical compositions including a sugar or mannose analog (e.g., 2-DG) and an inhibitor of at least one of PERK and GCN2 (e.g., an inhibitor of PERK and an inhibitor of GCN2) for treating cancer, and methods of treating cancer in a subject involving administration of these pharmaceutical compositions. Pharmaceutical compositions [or inducing death of cancer cells include a therapeutically effective amount of a pharmaceutical composition including: a pharmaceutically acceptable carrier, a sugar analog in an amount effective for inhibiting the growth of cancer cells, and an inhibitor of at least one of: PERK and GCN2 in an amount effective for blocking phosphorylation of eif2-1?t in the cancer cells, wherein the combined amounts of the sugar analog and the inhibitor of at least one of: PERK and GCN2 are sufficient for inducing death of the cancer cells.

Abstract: Compositions which modulate mitochondrial functions treat diseases associated with cells that are hyperactively using their endoplasmic reticulum. Screening assays identify agents which modulate mitochondrial functions.

Abstract: Methods of treating glioblastoma and pancreatic cancer are provided by the administration of a therapeutically effective amount of a hexose compound to a subject in need thereof The subject invention includes methods of treating brain and pancreatic cancer comprising the administration of a therapeutically effective amount of a mannose compound to a subject in need thereof The subject invention further includes methods of treating the proliferation of tumors comprising the administration of a therapeutically effective amount of 2-FM to a subject in need thereof.

Abstract: Glycolytic inhibitors are useful in the treatment of solid tumors by attacking anaerobic cells at the center on the tumor. 2-deoxyglucose, oxamate and various analogs thereof are identified as having a natural selective toxicity toward anaerobic cells, and will significantly increase the efficacy of standard cancer chemotherapeutic and radiation regiments as well as new protocols emerging with anti-angiogenic agents.

Abstract: Glycolytic inhibitors are useful in the treatment of solid tumors by attacking anaerobic cells at the center on the tumor. 2-deoxyglucose, oxamate and various analogs thereof are identified as having a natural selective toxicity toward anaerobic cells, and will significantly increase the efficacy of standard cancer chemotherapeutic and radiation regiments as well as new protocols emerging with anti-angiogenic agents.